From GRACE: New FDA Indication for First Line Tarceva in EGFR Mutation-Positive NSCLC May Be Good for Roche but BAD for Patients: Here’s Why


This week, we borrow a post from the excellent website of the Global Resource for Advancing Cancer Education (GRACE). GRACE founder and president Dr. Jack West is an oncologist who treats people with lung cancer. To see the original post, and to explore the many other resources offered by GRACE, click here.

New FDA Indication for First Line Tarceva in EGFR Mutation-Positive NSCLC May Be Good for Roche but BAD for Patients: Here’s Why

Continue reading…